JBJoshua M. Berlin

Joshua M. Berlin

*This is an algorithmically generated author record based on publicly available information.

Joshua M. Berlin has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Dermatology Emergencies

    by Roselyn Kellen, Joshua M. Berlin

    Dermatology is primarily an outpatient specialty. However, it is important to recognize certain conditions that require referral for inpatient management as well as for healthcare professionals to appreciate the types of patients who need to be triaged appropriately in the emergency room or urgent care setting. This article will serve to summarize some of the diagnostic features and management of these patients.

  • Actinic Keratosis

    by Berlin, Joshua M.

    Actinic keratoses are some of the most widely encountered lesions in dermatology practices. They represent the second most common reason for patients to visit a dermatologist. There are many different approaches available to treat actinic keratoses, and the dermatology nurse plays a pivotal part in educating patients about their choices. The purpose of this article is to review how these different treatments work and to address potential advantages and disadvantages of each.


    • 1 July 2011
      • Vol. 10  (7) , 718-22

    A randomized, placebo-controlled, double-blind study to evaluate the efficacy of a citrus bioflavanoid blend in the treatment of senile purpura.

    by Joshua M Berlin, David P Eisenberg, Mindy B Berlin, Robert A Sarro, Douglas R Leeman, Howard Fein

    Senile purpura is a common, chronic skin condition affecting more than 10 percent of individuals over the age of 50. Despite being a benign condition, the continual development of purpura lesions in afflicted patients is frequently a source of significant visual and social concern. To date, there are no known effective treatments for this condition. To evaluate the efficacy of a novel nutraceutical citrus bioflavonoid blend in improving the skin's appearance in patients with senile purpura. A six-week, randomized, multicenter, placebo-controlled, double-blind study was conducted to determine whether a uniquely formulated, oral citrus bioflavonoid supplement could treat active lesions of senile purpura while preventing new lesions from arising. Seventy patients with senile purpura were enrolled and 67 completed the study. Subjects were randomized into two groups receiving either a citrus bioflavonoid blend or placebo medication, which was taken orally twice daily for six weeks. Clinical evaluations were performed by blinded investigators at two locations. A statistically significant reduction in the number of new purpura lesions in the skin area undergoing clinical study was documented. At the end of six weeks, the citrus bioflavonoid blend treated group showed a 50 percent reduction in purpura lesions from baseline. Patient self-assessment of the effectiveness of the medication echoed the results of an investigator global assessment with a statistically significant improvement in the skin's appearance noted by the patients receiving the active medication. No adverse effects were noted by either the patients or investigators. This new treatment appears to both safely and effectively diminish skin bruising in patients with senile purpura.


  • Open Access

    Current and emerging treatment strategies for the treatment of actinic keratosis

    by Joshua M. Berlin

    Current and emerging treatment strategies for the treatment of actinic keratosis Joshua M BerlinDermatology Associates, PA, of the Palm Beaches, Boynton Beach, FL, USA Actinic keratoses are encountered by physicians worldwide on a daily basis. As these precancerous lesions can transform to skin carcinomas, it is important to understand the many available options to use as treatment. In recent years, new therapeutic options have emerged to treat this common condition. These treatments as well as a review of the literature of conventional therapies will be discussed.Keywords: actinic keratoses, squamous cell carcinoma, 5-fluorouracil


  • Open Access

    A rash on the legs and palms

    by Joshua M. Berlin, Sandra M. Goldberg


    • 1 July 2008
      • Vol. 7  (7) , 669-73

    Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery.

    by Joshua M Berlin, Darrell S Rigel

    Actinic keratoses are increasingly common skin lesions that are evaluated and treated by dermatologists on a daily basis. It is estimated that more than 90% of actinic keratoses in the US are treated by destructive therapies, such as cryosurgery. The purpose of this study was to evaluate the efficacy of sequential therapy of cryosurgery followed by diclofenac sodium 3% gel. This prospective, double-arm, multicenter, open-label, phase 4 study was performed at 82 community dermatology centers in the US. A total of 714 subjects who had a clinical diagnosis of actinic keratosis with between 5 and 15 lesions contained in a target area such as the forehead, scalp, and hands were enrolled in the study. These subjects were randomized into 2 arms of the study: cryosurgery alone and cryosurgery followed by diclofenac sodium 3% gel for a period of 90 days. Lesion counts were assessed at baseline, and 45, 75, 105, and 135 days after cryosurgery. Of the 521 patients enrolled in the study who successfully completed all of the visits concluding on day 135, 277 were in the cryosurgery alone arm and 244 were in the cryosurgery followed by diclofenac sodium 3% gel arm. At the conclusion of the study, 46% of the subjects in the cryosurgery followed by the use of diclofenac sodium 3% gel arm achieved 100% cumulative (target plus new lesions) lesion clearance compared to 21% in the cryosurgery alone arm (P < .0001). One hundred percent target lesion clearance was achieved in 64% of the subjects in the active arm compared to 32% in the cryosurgery alone arm (P < .0001). With the increased prevalence of actinic keratoses, it is important to consider and evaluate emerging therapeutic options. The sequential treatment with cryosurgery followed by diclofenac sodium 3% gel for 90 days is well tolerated and can provide a therapeutic modality that may provide patients with actinic keratoses a more successful outcome than monotherapy with cryosurgery by effectively treating clinical and subclinical lesions.


  • Radiotherapy for Rodent Ulcer Type of Basal Cell Carcinoma

    by Joshua M. Berlin, Douglas R. Leeman, Jerome J. Spunberg, Anne Lewis, Robert A. Sarro